Biotechnology in the Production of Recombinant Vaccine or Antigen for Animal Health

Abstract

Recombinant DNA (rDNA) technology has indeed made tremendous breakthrough in the discovery of various vaccines or diagnostic antigens. The advent of rDNA technology and its application in the industry has brought about a rapid growth of biotechnology companies for the production of the rDNA products in human and animal healthcare. The new generation vaccines prepared from the viral/microbial proteins; their fragments or the nucleic acid sequences have been attractive because of their stability, non-infectious nature, homogeneity as well as their cost-effectiveness. Several products are undergoing clinical trials and finally products approval by FDA/FAO/OIE is required before its use in human/animals. Products developed in the field of veterinary prophylactics and diagnostics will be most valuable for further development of rDNA products in the coming decades and advances in biotechnology have also created many legal issues particularly patent. The Biotech industry Guide would be useful for industrial approval, regulatory clearance to rDNA product and biosafety aspects. In view of high market potential for recombinant therapeutics as the case with human therapeutics, indigenous technology should also be developed for the veterinary field to develop a prophylactics and diagnostics. This general article provides collected information regarding production of recombinant proteins and their use in Veterinary science along with brief description of various heterologous expressed systems and their potential applications for the production of recombinant products.